CORDIS - Resultados de investigaciones de la UE
CORDIS

The making and breaking of ubiquitin chains in cholesterol metabolism

Objetivo

"Elevated levels of circulating LDL-cholesterol are a major determinant contributing to atherogenesis and coronary artery disease. Therefore, many studies address the central transcriptional pathways that regulate cholesterol metabolism. However, transcriptional regulation does not allow cells to quickly adapt to the cholesterol fluxes that they encounter. For this, rapid and reversible post-transcriptional modifications are used, in conjunction with transcriptional control. Ubiquitylation - the post-transcriptional conjugation of ubiquitin to proteins – is studied in relation to many cellular processes. Much less is known about the contribution of the ubiquitin-proteasomal-system (UPS) to regulation of lipid metabolism and development of cardiovascular disease.

I recently identified the E3-ubiquitin ligase IDOL as a novel post-transcriptional regulator of the LDLR pathway. My lab also recently identified two genes, the E3-ubiquitin ligase MARCH6 and the de-ubiquitylase USP2, for which no role in sterol metabolism was known, as important regulators of cellular cholesterol metabolism. With IDOL, these genes control key nodes of cholesterol synthesis and uptake and represent previously unrecognized mechanisms to control cholesterol homeostasis. To study the contribution of these genes to cholesterol metabolism, we will use state-of-the-art mutant mouse models, in vitro assays, and a unique collection of dyslipidemic patient material. Our goal is to characterize the contribution of these genes to cholesterol homeostasis and to examine their involvement in the development of dyslipidemia and atherosclerosis.

Investigating these novel regulatory systems will provide important mechanistic insight into the contribution of the UPS to cholesterol metabolism in health and disease. As components of the UPS are amenable to pharmacological manipulation these studies could potentially lead to novel targets for treatment of hypercholesterolemia and coronary artery disease."

Convocatoria de propuestas

ERC-2013-CoG
Consulte otros proyectos de esta convocatoria

Régimen de financiación

ERC-CG - ERC Consolidator Grants

Institución de acogida

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Aportación de la UE
€ 1 999 998,00
Dirección
MEIBERGDREEF 15
1105AZ Amsterdam
Países Bajos

Ver en el mapa

Región
West-Nederland Noord-Holland Groot-Amsterdam
Tipo de actividad
Higher or Secondary Education Establishments
Investigador principal
Noam Zelcer (Dr.)
Contacto administrativo
Gulseren Yalvac (Ms.)
Enlaces
Coste total
Sin datos

Beneficiarios (1)